


## Tarlox-TKI

<b>Cat. No.:</b>	HY-43533		
<b>CAS No.:</b>	2135696-72-7		
<b>Molecular Formula:</b>	C <sub>19</sub> H <sub>18</sub> BrClN <sub>6</sub> O		
<b>Molecular Weight:</b>	461.74		
<b>Target:</b>	EGFR		
<b>Pathway:</b>	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 100 mg/mL (216.57 mM; Need ultrasonic)			
		Solvent Concentration	Mass	
			1 mg	5 mg
	<b>Preparing Stock Solutions</b>	1 mM	2.1657 mL	10.8286 mL
		5 mM	2.1657 mL	4.3314 mL
		10 mM	0.2166 mL	1.0829 mL
	Please refer to the solubility information to select the appropriate solvent.			
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.41 mM); Clear solution  2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (5.41 mM); Clear solution			

### BIOLOGICAL ACTIVITY

<b>Description</b>	Tarlox-TKI, the active metabolite of Tarloxotinib, is an irreversible pan-ErbB TKI (Tarlox-TKI) <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	EGFR
<b>In Vitro</b>	Epidermal Growth Factor Receptor (EGFR, HER1) is an attractive therapeutic target for many cancer types. Tarlox-TKI is a dose-potent EGFR inhibitor <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

---

[1]. Victoria Jackson-Patel, et al. Hypoxia tumour targeting with Tarloxotinib to improve clinical outcomes for patients with EGFR-dependent malignancies.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA